Medicenna Therapeutics Company Profile - aVenture Research
Medicenna aims to make interleukin therapy selective by refining native cytokines into Superkines, engineered interleukins with properties natural ones cannot achieve. It evolves them for receptor selectivity, potency, half-life and tissue distribution, then fuses or masks them rather than giving natural cytokines: BiSKIT links Superkines to antibodies or other proteins to modulate two signaling pathways at once, and T-MASK therapies carry a mask that blocks activity in healthy tissue until disease-site enzymes remove it.
Medicenna's selectivity comes from targeting receptors and suppressive cells enriched in tumors rather than healthy tissue. MDNA11 is a long-acting beta-enhanced IL-2 Superkine that signals through the IL-2 beta receptor on immune cells, while Bizaxofusp, an IL-4 Superkine therapy, targets myeloid-derived suppressor cells in tumors; the IL-4 receptor is expressed in malignant brain tumors and their microenvironment but not in healthy brain tissue, and Bizaxofusp induces immunogenic cell death in tumor cells, releasing tumor antigens and danger signals.
Medicenna is a clinical-stage immunotherapy company developing engineered interleukins—IL-2, IL-4 and IL-13 Superkines via directed evolution—rather than conventional molecules.